The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo ...
Enrollment in the Phase 1/2 ASTRA study is set to start in the first half of 2025. The study will observe the safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback